IP Library Granted Patent US 11,452,699
Granted Patent B2
US 11,452,699 · App. 16/444,296 · Granted Sep 27, 2022

Method of treating or preventing tumors of the central nervous system

Inventors: Joaquin J. Jimenez (Miami, FL); Niven Rajin Narain (Cambridge, MA); Rangaprasad Sarangarajan (Boylston, MA); John Patrick McCook (Frisco, TX)
Assignee: Berg LLC
A61K31/122
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,452,699
App. No.
16/444,296
Granted
Sep 27, 2022
Kind
B2
Abstract

The invention provides methods and compositions for treatment of a subject with a central nervous system (CNS) tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject exhibits at least one CNS abnormality as a result of the tumor.

Claims (27)

1. A method of treating a central nervous system (CNS) tumor in a subject exhibiting at least one CNS abnormality as a result of the presence of the CNS tumor comprising administering to the subject a composition comprising a Coenzyme Q10 (CoQ10) compound, thereby treating the CNS tumor, wherein the at least one CNS abnormality exhibited by the subject as a result of the presence of the CNS tumor comprises decreased muscle control, and treatment of the subject results in amelioration of the decreased muscle control in the subject.

2. The method of claim 1 , wherein the at least one CNS abnormality further comprises a CNS abnormality selected from the group consisting of a headache, a seizure, a change in memory, loss of short term memory, a change in temperament, sudden onset of panic attacks induced by familiar situations, a change in intellectual function, inability to do math, inability to find objects in plain sight; confusion, disorientation, becoming lost in a familiar location; blurred vision, loss of vision, loss of peripheral vision, double vision, dizziness, hearing problems, ringing in ears, buzzing in ears, lack of coordination, decreased sensation, weakness, paralysis, paraplegia, quadriplegia, difficulty with walking, change in gait, difficulty with speech, and balance problems.

3. The method of claim 1 , wherein the at least one CNS abnormality comprises at least 2 CNS abnormalities.

4. The method of claim 1 , wherein the at least one CNS abnormality comprises 3-10 CNS abnormalities.

5. A method of treatment of a secondary CNS tumor from a primary tumor in a subject exhibiting at least one CNS abnormality as a result of the presence of the secondary CNS tumor comprising administering to the subject a composition comprising a Coenzyme Q10 (CoQ10) compound, thereby treating the secondary CNS tumor, wherein the at least one CNS abnormality exhibited by the subject as a result of the presence of the secondary CNS tumor comprises decreased muscle control, and treatment of the subject results in amelioration of the decreased muscle control in the subject.

6. The method of claim 5 , wherein the primary tumor is a pediatric tumor.

7. The method of claim 6 , wherein the pediatric tumor is a leukemia.

8. The method of claim 5 , wherein the primary tumor was treated with CNS radiation.

9. The method of claim 5 , wherein the primary tumor was treated by administration of a chemotherapeutic agent to the CNS.

10. The method of claim 5 , wherein the secondary tumor is identified at least one year after treatment of the primary tumor is concluded.

11. The method of claim 5 , wherein the secondary tumor is identified at least three years after treatment of the primary tumor is concluded.

12. The method of claim 5 , wherein the secondary tumor is identified at least five years after treatment of the primary tumor is concluded.

13. The method of claim 5 , wherein the secondary tumor is identified at least ten years after treatment of the primary tumor is concluded.

14. The method of claim 1 , wherein the CoQ10 compound is CoQ10.

15. The method of claim 1 , wherein the tumor is a leukemic tumor.

16. The method of claim 1 , wherein the CoQ10 compound is administered topically.

17. The method of claim 1 , wherein the CoQ10 compound is administered parenterally.

18. The method of claim 1 , wherein the CoQ10 compound is administered by injection or infusion.

19. The method of claim 18 , wherein the CoQ10 compound is not administered directly to the CNS.

20. The method of claim 1 , further comprising administration of an additional agent.

21. The method of claim 20 , wherein the additional agent is a chemotherapeutic agent for treatment of a tumor.

22. The method of claim 1 , wherein the tumor is further treated with radiation therapy.

23. The method of claim 1 , wherein the tumor is further treated with surgery.

24. The method of claim 1 , wherein the subject is human.

25. The method of claim 5 , wherein the CoQ10 compound is CoQ10.

26. The method of claim 5 , wherein the CoQ10 compound is administered by injection or infusion.

27. The method of claim 5 , wherein the subject is human.

Assignments (8)
SECURITY INTEREST Recorded Aug 29, 2025
From: BPGBIO INC.
To: BERG SURVIVOR’S TRUST; BERG, KARA ANN; THLIVERIS, ANDREW T.
Reel/Frame 072805/0303 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 8147825 WAS ADDED PREVIOUSLY RECORDED AT REEL: 70903 FRAME: 693. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Apr 30, 2025
From: BPGBIO INC.
To: PHOENIX GENESIS LLC
Reel/Frame 071285/0001 →
SECURITY INTEREST Recorded Apr 21, 2025
From: BPGBIO INC.
To: PHOENIX GENESIS LLC
Reel/Frame 070903/0693 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2023
From: BERG LLC
To: BPGBIO, INC.
Reel/Frame 063842/0405 →
CHANGE OF NAME Recorded Aug 28, 2019
From: BERG PHARMA LLC
To: BERG LLC
Reel/Frame 050206/0362 →
CHANGE OF NAME Recorded Aug 28, 2019
From: BERG THERAPEUTICS, LLC
To: BERG PHARMA LLC
Reel/Frame 050206/0359 →
CHANGE OF NAME Recorded Aug 28, 2019
From: CYTOTECH LABS, LLC
To: BERG THERAPEUTICS, LLC
Reel/Frame 050200/0683 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2019
From: JIMENEZ, JOAQUIN J.; NARAIN, NIVEN RAJIN; SARANGARAJAN, RANGAPRASAD; MCCOOK, JOHN PATRICK
To: CYTOTECH LABS, LLC
Reel/Frame 049809/0109 →